Skip to main navigation

About Us
Our Science
- What is Gene Therapy
- The Taysha Strategy
Pipeline
- Other Programs
- TSHA-102 in Rett Syndrome
Healthcare Professionals
Patients & Caregivers
Investors
Careers
- Heart of Taysha
- Open Positions
Contact

Quarterly Reports

Overview
Press Releases
Events & Presentations
Financials & Filings
Corporate Governance
Shareholder Resources
- FAQs
- Contact IR
Stock Information
Analyst Coverage

Show all

2025

Fourth Quarter

Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
Form 10-K

Third Quarter

Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Form 10-Q

Second Quarter

Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Form 10-Q

First Quarter

Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update
Form 10-Q

2024

Fourth Quarter

Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update
Form 10-K

Third Quarter

Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Form 10-Q

Second Quarter

Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Form 10-Q

First Quarter

Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update
Form 10-Q

2023

Full Year

Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
Form 10-K

Third Quarter

Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
Form 10-Q

Second Quarter

Taysha Gene Therapies Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial and Provides Corporate Update with Second Quarter 2023 Financial Results
Form 10-Q

First Quarter

Taysha Gene Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
Form 10-Q

2022

Fourth Quarter

Taysha Gene Therapies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Form 10-K

Third Quarter

Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Form 10-Q

Second Quarter

Taysha Gene Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Form 10-Q

First Quarter

Taysha Gene Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update
Form 10-Q

2021

Fourth Quarter

Taysha Gene Therapies Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Form 10-K

Third Quarter

Taysha Gene Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Second Quarter

Taysha Gene Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Form 10-Q

First Quarter

Taysha Gene Therapies Reports First Quarter 2021 Financial Results and Provides a Corporate Update
Form 10-Q

2020

Fourth Quarter

Taysha Gene Therapies Reports Full-Year 2020 Financial Results and Provides a Corporate Update
Form 10-K

Third Quarter

Taysha Gene Therapies Reports Third Quarter 2020 Financial Results and Provides Business Update
Form 10-Q

Print Page
RSS Feeds
Email Alerts
Contact IR

About Us
Our Science
- What is Gene Therapy
- The Taysha Strategy
Pipeline
- Other Programs
- TSHA-102 in Rett Syndrome
Healthcare Professionals
Patients & Caregivers
Investors
Careers
- Heart of Taysha
- Open Positions
Contact

Corporate Headquarters
3000 Pegasus Park Drive, Suite 1430
Dallas, Texas 75247

Laboratory Facility
Morrisville, NC 27560

Copyright 2026 Taysha Gene Therapies | Privacy Notice Terms of Service